News + Font Resize -

Sigma-Aldrich introduces panorama human signal transduction protein array
St. Louis | Monday, May 29, 2006, 08:00 Hrs  [IST]

Sigma-Aldrich, announces the latest addition to its functional protein array product line, the Panorama Human Signal Transduction Protein Array. Developed in conjunction with Procognia Ltd, UK, and licensed exclusively through Sigma-Aldrich, the Signal Transduction array contains 259 full-length proteins that are involved in key cellular processes including proliferation, differentiation and apoptosis.

This array employs a unique fusion tag that has been shown to confer protein functionality and that also serves to select, tether and uniformly orientate proteins on a streptavidin-coated glass slide. This technology offers the unique advantage of allowing proteins to behave in a sterically unencumbered manner, thereby increasing the potential for acquiring data that is more closely representative of native physiological states.

Signal transduction describes cellular response to external or internal stimuli and often results in fundamental cellular changes such as regulating gene expression or controlling cell proliferation.

"With a multiplex assay format, the researcher is empowered to recognize signalling transduction in disease states and to characterize specific proteins involved in the intricate cascade of events that follow," said Richard Pembrey, market segment manager, functional proteomics. "With the first commercially-available array specifically targeting signal transduction, researchers can study the function of key protein families by performing parallel assays for selectivity with other proteins, antibodies, peptides, kinases and drug candidates," he added.

The Panorama Signal Transduction Functional Protein Array extends Sigma-Aldrich's market-leading array portfolio for proteomic research and exemplifies our commitment to providing the Life Science community with innovative technologies designed to enhance and accelerate scientific discovery.

Post Your Comment

 

Enquiry Form